Related Experiment Video
Updated: Jan 30, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
Rainer Girgert1, Günter Emons1, Carsten Gründker1
1Department of Gynecology and Obstetrics, University Medicine Göttingen, Göttingen, Germany.
Abstract:
Estrogen receptors are important regulators of the growth of breast tumors. Three different receptors for estrogens have been identified in breast tumors, two nuclear receptors, ERα and ERβ, and a G-protein coupled estrogen receptor 1 (GPER) that initiates non-genomic effects of estrogens in the cytosol. Recent findings show that the stimulation of cytoplasmic ERα and ERβ also triggers non-genomic signaling pathways. The treatment of breast cancer with anti-estrogens depends on the presence of ERα. About 40% of all breast cancers, however, do not express ERα. One subgroup of these tumors overexpress Her-2, another important group is designated as triple-negative breast cancer, as they neither express ERα, nor progesterone receptors, nor do they overexpress Her-2. This review addresses the signaling of ERβ and GPER in ERα-negative breast tumors. In addition to the well-established EGF-receptor transactivation pathways of GPER, more recent findings of GPER-dependent activation of FOXO3a, the Hippo-pathway, and HOTAIR-activation are summarized.
Insights
Estrogen receptor signaling in ERα-negative breast tumors is explored. This review details the roles of ERβ and GPER in non-genomic pathways, offering insights into potential therapeutic targets for difficult-to-treat breast cancers.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Estrogen receptors (ERα, ERβ, GPER) regulate breast tumor growth.
- Anti-estrogen therapy effectiveness relies on ERα presence.
- ERα-negative breast cancers, including triple-negative, lack ERα and require alternative treatment strategies.
Purpose of the Study:
- To review the signaling pathways of ERβ and GPER in ERα-negative breast tumors.
- To highlight recent findings on GPER-mediated non-genomic effects.
- To explore potential therapeutic targets beyond ERα.
Main Methods:
- Literature review of signaling pathways involving ERβ and GPER.
- Analysis of non-genomic signaling mechanisms.
- Summary of GPER-dependent activation of FOXO3a, Hippo-pathway, and HOTAIR.
Main Results:
- ERβ and GPER play significant roles in ERα-negative breast tumor signaling.
- GPER mediates non-genomic effects, including EGF-receptor transactivation.
- Emerging evidence shows GPER activates FOXO3a, Hippo-pathway, and HOTAIR.
Conclusions:
- ERβ and GPER represent crucial targets for ERα-negative breast cancer treatment.
- Understanding these pathways can lead to novel therapeutic interventions.
- Further research into GPER-mediated signaling is warranted for clinical application.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Negative Regulator Molecules
Positive, Negative, and Zero Work
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Endocrine Signaling
Bacterial Signaling

